Cargando…
The Extended Use of Eculizumab in Pregnancy and Complement Activation–Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys—The Future Is Now?
Excessive complement activation is involved in the pathogenesis of many diseases and the kidney is an organ with particular susceptibility to complement-mediated injury. Apart from paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), there are several other diseas...
Autor principal: | Stefanovic, Vedran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463259/ https://www.ncbi.nlm.nih.gov/pubmed/30909646 http://dx.doi.org/10.3390/jcm8030407 |
Ejemplares similares
-
Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021) -
Complement activation and effect of eculizumab in scleroderma renal crisis
por: Devresse, Arnaud, et al.
Publicado: (2016) -
Intrauterine Fetal Gene Therapy: Is That the Future and Is That Future Now?
por: Peddi, Nikhil Chowdary, et al.
Publicado: (2022) -
Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal Outcomes
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2023) -
Eculizumab and Complement Activation in Anti−glomerular Basement Membrane Disease
por: Nithagon, Pravarut, et al.
Publicado: (2021)